Immune cell therapy shows promise for Tough-to-Treat lupus and scleroderma
NCT ID NCT06947473
First seen Sep 30, 2025 · Last updated Apr 28, 2026 · Updated 24 times
Summary
This study tests a new treatment using specially engineered immune cells from cord blood to target and calm overactive immune cells in people with severe lupus, scleroderma, or Sjogren's syndrome with lung complications. The main goal is to check safety, especially any serious side effects within the first month. About 45 participants will receive a single infusion and be followed for up to 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
Conditions
Explore the condition pages connected to this study.